Abstract:Objective To investigate the clinical characteristics and prognostic of acute myeloid leukemia (AML) patients with MLL-AF-6 fusion gene.Methods Samples from eight acute myeloid leukemia patients with MLL-AF-6 fusion gene hospitalized in Department of Hematology of Anhui Provincial Hospital were collected.The correlation between clinical features,immunophenotype,rate of complete remission after the first induction therapy,overall survival,response to allo-HSCT or prognosis of patients and the dynamic change of MLL-AF6 fusion gene which was accessed by multiplex nested reverse transcription-polymerase chain reaction was.Results From February 2009 to August 2013,472 patients were diagnosed as acute leukemia (AL),including 285 AML patients,and eight of them with MLL-AF-6 fusion gene,who were account for 1.69 ％ (8/472) of AL and 2.80 ％ (8/285) of AML.According to WHO classification,all MLL-AF6 fusion gene-positive patients were classified into M1 (1 case),M2 (2 cases),M4 (2 cases),M5 (3 cases),in which M4/M5 were accounted for 62.50 ％ (5/8).After first induction therapy,the complete response (CR) and overall survival (OS) rated of AML patients with MLL-AF6 were 62.50 ％ (5/8) and 50.0 ％ (4/8),respectively.At the end of first course therpy,two of four patients receiving chemotherapy alone had negative detection of MLL-AF-6 fusion gene.During the follow-up period,one of them achieved hematologic complete remission and survived for 26 months,and the other had recurrence six months after diagnosis and died after treatment.The other 2 patients receiving chemotherapy alone had no change in MLL-AF6 fusion gene expression,who didn 't achieve hematologic complete remission and died finally.Four patients received bone marrow transplantation at the end of first course.Three of them became MLL-AF6 fusion gene negative and achieved hematologic complete remission,and survived with mean survival 28 months.One patient who received bone marrow transplantation did not become MLL-AF6 fusion gene negative and died after transplantation.Conclusions There is high incidence of MLL-AF6 fusion gene rearrangement in M4/M5 patients,which is often accompanied with hyperleukocytosis,organ infiltration,worse therapeutic effects,high recurrence rate and poor prognosis.HSCT is a reasonable treatment to improve the prognosis of those patients.Monitor the changes of MLL-AF6 fusion gene during the treatment can help to indicate the prognosis of patients.

PHF6 Mutation is Associated with Poor Outcome in Acute Myeloid Leukaemia.

PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis

PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway

PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia

Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting

PHF6 suppresses self-renewal of leukemic stem cells in AML

Leukemia-mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness

PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Clinical Characteristics and Prognostic of 8 Cases of Acute Myeloid Leukemia Patients with MLL-AF-6 Fusion Gene

FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.

Haploidentical Haematopoietic Stem Cell Transplantation for TP53‐mutated Acute Myeloid Leukaemia

Expression Level of GAS6-mRNA Influences the Prognosis of Acute Myeloid Leukemia Patients with Allogeneic Hematopoietic Stem Cell Transplantation

Dead/H-Box Helicase 11 (DDX11) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice

PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients

The Clinical Analysis of Haploidentical Stem Cell Transplantation in Myelodysplastic Syndrome-Associated Acute Myeloid Leukemia

The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China